probucol has been researched along with Disease Models, Animal in 86 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The nanoencapsulation increased the plasma and brain concentration of probucol significantly compared with the mice that was given the same dosage of probucol without capsulation, and significantly suppressed the neuroinflammation and neurodegeneration." | 7.88 | Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. ( Al-Salami, H; Brook, E; D'Alonzo, Z; Fimognari, N; Graneri, L; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Stephenson, A; Takechi, R, 2018) |
| "This study demonstrated that probucol has some impact on malaria by oxidative stress through the induction of host plasma vitamin E deficiency." | 7.83 | Probucol dramatically enhances dihydroartemisinin effect in murine malaria. ( Anh, DT; Ishida, N; Kume, A; Shichiri, M; Suzuki, H, 2016) |
| "The aim of the present study was to develop a model of hypertriglyceridemic (HTG) acute pancreatitis and to investigate the effects of probucol in this model." | 7.78 | Development of a novel model of hypertriglyceridemic acute pancreatitis in hamsters: protective effects of probucol. ( Cui, X; Guo, C; Hu, G; Li, H; Liu, G; Liu, L; Liu, Y; Shen, J; Tang, Y; Wang, X; Wang, Y; Yu, Y; Zhao, Y, 2012) |
| "This study was designed to evaluate the effects of the antioxidant probucol on myocardial oxidative stress and collagen remodeling by determining type I and III collagen together with relevant collagen mRNA expressions in both the infarcted and noninfarcted myocardium in post-myocardial infarction (MI) rats." | 7.75 | Antioxidant probucol attenuates myocardial oxidative stress and collagen expressions in post-myocardial infarction rats. ( Lei, J; Wang, JF; Zhang, YL; Zhou, SX; Zhou, Y, 2009) |
| "In the present study, we compared the effects of alpha-tocopherol and probucol, antioxidants, on the healing of acetic acid-induced gastric ulcers in 8-, 48- and 96-week-old rats." | 7.74 | Influence of aging on gastric ulcer healing activities of the antioxidants alpha-tocopherol and probucol. ( Ishihara, M; Ito, M; Kojima, R, 2008) |
| "These findings indicate that alpha-tocopherol and probucol suppress allergic responses in asthma model mice, although these two drugs cause suppression in different ways that are unrelated to antioxidation." | 7.73 | Effects of alpha tocopherol and probucol supplements on allergen-induced airway inflammation and hyperresponsiveness in a mouse model of allergic asthma. ( Murata, T; Nagai, H; Okamoto, N; Tamai, H; Tanaka, H, 2006) |
| "To elucidate processes by which the antioxidant probucol increases lesion size at the aortic sinus and decreases atherosclerosis at more distal sites in apolipoprotein E-deficient (apoE(-/-)) mice." | 7.73 | Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. ( Beck, K; Choy, K; Croft, KD; Hou, JY; Leichtweis, SB; Mori, TA; Png, FY; Stocker, R; Thomas, SR; Wu, BJ, 2005) |
| "A high incidence of sudden death due to ventricular fibrillation (VF) has been observed in dogs under chronic treatment with probucol, a new hypocholesterolemic agent." | 7.66 | Adrenergaically mediated ventricular fibrillation in probucol-treated dogs: roles of alpha and beta adrenergic receptors. ( Besch, HR; Elharrar, V; Molello, J; Watanabe, AM; Zipes, DP, 1979) |
| "Probucol decreased the increase of CRP concentration and attenuated atrial oxidative stress caused by atrial tachypacing." | 5.35 | Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. ( Dong, DL; Gong, YT; Li, BX; Li, WM; Li, Y; Liu, W; Shan, HB; Sheng, L; Xue, HJ; Yang, BF; Yang, N; Yang, SS, 2009) |
| "Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration, whereas probucol is a vascular protectant and reduces stent restenosis by improving the lumen dimension at the stent placement site." | 5.33 | Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. ( Ahn, YK; Cha, KS; Cho, JG; Hong, YJ; Hur, SH; Hyun, DW; Jeong, MH; Kang, JC; Kim, JH; Kim, KB; Kim, MH; Kim, W; Park, HW; Park, JC; Park, JT, 2005) |
| "We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia." | 4.84 | [Animal models for steroid-induced osteonecrosis]. ( Iwamoto, Y; Miyanishi, K; Motomura, G; Nishida, K; Sueishi, K; Yamamoto, T, 2007) |
| "The nanoencapsulation increased the plasma and brain concentration of probucol significantly compared with the mice that was given the same dosage of probucol without capsulation, and significantly suppressed the neuroinflammation and neurodegeneration." | 3.88 | Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. ( Al-Salami, H; Brook, E; D'Alonzo, Z; Fimognari, N; Graneri, L; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Stephenson, A; Takechi, R, 2018) |
| "We have shown that probucol-induced HDL deficiency impairs the ability of established lesions to regress in response to reversal of the genetic hypercholesterolemia in Apoe knockout mice." | 3.88 | HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution. ( Hoekstra, M; Lendvai, Z; van der Sluis, RJ; Van Eck, M; Verwilligen, RAF; Wever, R, 2018) |
| " Based on previous studies demonstrating the important antioxidant and anti-hyperlipidemic effect of morpholine and 1,4-benzo(x/thi)azine derivatives (A-E), we hereby present the design, synthesis and pharmacological evaluation of novel dual-acting molecules as a therapeutic approach for atherosclerosis." | 3.85 | Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity. ( Katselou, MG; Kourounakis, AP; Matralis, AN, 2017) |
| "This study demonstrated that probucol has some impact on malaria by oxidative stress through the induction of host plasma vitamin E deficiency." | 3.83 | Probucol dramatically enhances dihydroartemisinin effect in murine malaria. ( Anh, DT; Ishida, N; Kume, A; Shichiri, M; Suzuki, H, 2016) |
| "The aim of the present study was to develop a model of hypertriglyceridemic (HTG) acute pancreatitis and to investigate the effects of probucol in this model." | 3.78 | Development of a novel model of hypertriglyceridemic acute pancreatitis in hamsters: protective effects of probucol. ( Cui, X; Guo, C; Hu, G; Li, H; Liu, G; Liu, L; Liu, Y; Shen, J; Tang, Y; Wang, X; Wang, Y; Yu, Y; Zhao, Y, 2012) |
| " Probucol is a compound that reduces HDL-C levels but also reduces atherosclerosis in animal models and xanthomas in humans." | 3.77 | Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. ( Billheimer, JT; Komaru, Y; Li, X; Rader, DJ; Tanigawa, H; Yamamoto, S, 2011) |
| "This study was designed to evaluate the effects of the antioxidant probucol on myocardial oxidative stress and collagen remodeling by determining type I and III collagen together with relevant collagen mRNA expressions in both the infarcted and noninfarcted myocardium in post-myocardial infarction (MI) rats." | 3.75 | Antioxidant probucol attenuates myocardial oxidative stress and collagen expressions in post-myocardial infarction rats. ( Lei, J; Wang, JF; Zhang, YL; Zhou, SX; Zhou, Y, 2009) |
| "In the present study, we compared the effects of alpha-tocopherol and probucol, antioxidants, on the healing of acetic acid-induced gastric ulcers in 8-, 48- and 96-week-old rats." | 3.74 | Influence of aging on gastric ulcer healing activities of the antioxidants alpha-tocopherol and probucol. ( Ishihara, M; Ito, M; Kojima, R, 2008) |
| "Pretreatment with cariporide in the setting of ischemia-reperfusion injury provides greater protection against the development of diastolic abnormalities than probucol when Celsior solution is used for both arrest and preservation." | 3.73 | Na+/H+ exchange inhibition and antioxidants lack additive protective effects after reperfusion injury in the working heterotopic rat heart isograft. ( Curtis, LJ; Rabkin, DG; Spotnitz, HM; Weinberg, AD, 2005) |
| "To elucidate processes by which the antioxidant probucol increases lesion size at the aortic sinus and decreases atherosclerosis at more distal sites in apolipoprotein E-deficient (apoE(-/-)) mice." | 3.73 | Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. ( Beck, K; Choy, K; Croft, KD; Hou, JY; Leichtweis, SB; Mori, TA; Png, FY; Stocker, R; Thomas, SR; Wu, BJ, 2005) |
| "These findings indicate that alpha-tocopherol and probucol suppress allergic responses in asthma model mice, although these two drugs cause suppression in different ways that are unrelated to antioxidation." | 3.73 | Effects of alpha tocopherol and probucol supplements on allergen-induced airway inflammation and hyperresponsiveness in a mouse model of allergic asthma. ( Murata, T; Nagai, H; Okamoto, N; Tamai, H; Tanaka, H, 2006) |
| " To clarify the mechanisms underlying vascular dysfunction and oxidative stress in hypercholesterolemia, we compared the effects of antioxidant probucol with those of pravastatin on aortic stiffness, phenotypic modulation, oxidative stress, and NAD(P)H oxidase essential subunit p22(phox) expression in aortic medial SM cells of cholesterol-fed rabbits by using color image analysis of immunostained sections." | 3.71 | Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. ( Aoyagi, S; Fujii, T; Hiromoto, M; Itoh, S; Matsuzaki, M; Tanaka, M; Toma, Y; Tomochika, Y; Umemoto, S, 2002) |
| "We investigated the effect of probucol, a lipid-lowering agent with antioxidant properties, on HCl plus ethanol-induced gastric mucosal injury and on the healing of acetic acid-induced gastric ulcers in rats." | 3.70 | Anti-ulcer effects of antioxidants: effect of probucol. ( Ishihara, M; Ito, M; Suzuki, Y, 1998) |
| "A high incidence of sudden death due to ventricular fibrillation (VF) has been observed in dogs under chronic treatment with probucol, a new hypocholesterolemic agent." | 3.66 | Adrenergaically mediated ventricular fibrillation in probucol-treated dogs: roles of alpha and beta adrenergic receptors. ( Besch, HR; Elharrar, V; Molello, J; Watanabe, AM; Zipes, DP, 1979) |
| "Sprague Dawley rats were orally administrated with probucol at different dosage or vehicle for 5 days and subjected to a CA model by electrical stimulation, followed by cardiopulmonary resuscitation (CPR)." | 1.46 | Probucol Protects Rats from Cardiac Dysfunction Induced by Oxidative Stress following Cardiopulmonary Resuscitation. ( Che, B; Ho, D; Hou, H; Lin, V; Lu, Z; May, A; Shaw, PX; Tran, K; Xiao, X; Zhang, J, 2017) |
| "Cancer metastasis is the main cause for the high mortality in breast cancer patients." | 1.43 | pH-Responsive Wormlike Micelles with Sequential Metastasis Targeting Inhibit Lung Metastasis of Breast Cancer. ( Bao, X; Cao, H; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z, 2016) |
| "Probucol treatment significantly protected against the behavioral and hippocampal biochemical changes induced by STZ." | 1.42 | Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice. ( Colle, D; de Bem, AF; de Oliveira, J; Dos Santos, AA; Farina, M; Hort, MA; Moreira, ELG; Peres, KC; Ribeiro, RP; Santos, DB, 2015) |
| "Probucol treatment has beneficial effects on serum parameters, hepatic steatosis, and lobular inflammation in high-fat diet-induced NASH possibly by up-regulating FXR expression." | 1.40 | [Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism]. ( Gao, J; Liu, B; Wu, R; Wu, X; Xiao, X; Zhang, W; Zhang, X, 2014) |
| "Probucol is a lipid-lowering drug that is often prescribed for the treatment of familial hypercholesterolemia." | 1.40 | Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits. ( Bilal Waqar, A; Fan, J; Kang, D; Koike, T; Li, S; Liang, J; Niimi, M; Shiomi, M; Wang, Y, 2014) |
| " Our data suggest that the two studied toxic models (QA and 3-NP) or the combined model (QA plus 3-NP) can generate complex patterns of damage, which involve metabolic compromise, ROS formation, and oxidative stress." | 1.38 | Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. ( Colle, D; Farina, M; Hartwig, JM; Soares, FA, 2012) |
| "Probucol decreased the increase of CRP concentration and attenuated atrial oxidative stress caused by atrial tachypacing." | 1.35 | Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. ( Dong, DL; Gong, YT; Li, BX; Li, WM; Li, Y; Liu, W; Shan, HB; Sheng, L; Xue, HJ; Yang, BF; Yang, N; Yang, SS, 2009) |
| "Probucol and warfarin were administered beginning 1 to 2 weeks prior to steroid injection." | 1.35 | Risk factors for developing osteonecrosis after prophylaxis in steroid-treated rabbits. ( Hirota, Y; Iwamoto, Y; Kondo, K; Miyanishi, K; Motomura, G; Yamamoto, T, 2008) |
| "Probucol is known to be a potent hypolipidemic drug to regress xanthoma formation and carotid atherosclerosis in conjunction with a marked reduction in HDL-cholesterol levels." | 1.34 | Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits. ( Hong, SC; Wu, ZH; Zhao, SP, 2007) |
| "Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration, whereas probucol is a vascular protectant and reduces stent restenosis by improving the lumen dimension at the stent placement site." | 1.33 | Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. ( Ahn, YK; Cha, KS; Cho, JG; Hong, YJ; Hur, SH; Hyun, DW; Jeong, MH; Kang, JC; Kim, JH; Kim, KB; Kim, MH; Kim, W; Park, HW; Park, JC; Park, JT, 2005) |
| "Probucol did not increase human SR-BI protein in the liver of transgenic mice carrying the entire human SR-BI genome." | 1.33 | Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. ( Hirano, K; Ikegami, C; Koseki, M; Maruyama, T; Masuda, D; Matsuura, F; Nakagawa-Toyama, Y; Shimomura, I; Tsujii, K; Ueda, Y; Yamashita, S; Zhang, Z, 2005) |
| "Probucol is a hypolipidemic agent and has antioxidant activity, which may inhibit the oxidative modification of low-density lipoprotein cholesterol." | 1.33 | Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion. ( Al-Ghazali, R; Jinzhen, W; Ruixing, Y; Wenwu, L, 2006) |
| "Probucol was then tested in vivo in 8 coronary arteries of 4 pigs (1000 mg/day orally beginning 7 days before stenting) and was compared to placebo (10 coronary arteries, 5 pigs) 28 days after stenting." | 1.32 | Effect of probucol on neointimal thickening in a stent porcine restenosis model. ( Daida, H; Kurata, T; Miyauchi, K; Sato, H; Yokoyama, T, 2004) |
| "We have established a reproducible stenosis model in hypercholesterolemic hamsters, and the process of arterial stenosis by thrombus or neointima was studied and compared with that in normal hamsters." | 1.31 | Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters. ( Abe, A; Kozawa, O; Matsuno, H; Niwa, M; Takiguchi, Y; Uematsu, T, 2001) |
| "Probucol treatment also significantly reduced high-density lipoprotein (HDL) levels in apoE-deficient mice, but not in LDLR-deficient mice." | 1.31 | Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice. ( Chen, Z; Ishibashi, S; Shimano, H; Yamada, N; Yoshikawa, T, 2001) |
| "Focal segmental glomerulosclerosis is a steroid-resistant glomerular disease characterized by foot process flattening and heavy proteinuria." | 1.30 | Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. ( Binder, CJ; Exner, M; Kerjaschki, D; Weiher, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.49) | 18.7374 |
| 1990's | 15 (17.44) | 18.2507 |
| 2000's | 38 (44.19) | 29.6817 |
| 2010's | 28 (32.56) | 24.3611 |
| 2020's | 2 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Katselou, MG | 1 |
| Matralis, AN | 1 |
| Kourounakis, AP | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Xie, Y | 1 |
| Song, A | 1 |
| Zhu, Y | 1 |
| Jiang, A | 1 |
| Peng, W | 1 |
| Zhang, C | 1 |
| Meng, X | 1 |
| Huang, JL | 1 |
| Yu, C | 1 |
| Su, M | 1 |
| Yang, SM | 1 |
| Zhang, F | 1 |
| Chen, YY | 1 |
| Liu, JY | 1 |
| Jiang, YF | 1 |
| Zhong, ZG | 1 |
| Wu, DP | 1 |
| Xiao, X | 2 |
| Hou, H | 1 |
| Lin, V | 1 |
| Ho, D | 1 |
| Tran, K | 1 |
| Che, B | 1 |
| May, A | 1 |
| Zhang, J | 1 |
| Lu, Z | 2 |
| Shaw, PX | 1 |
| de Paula Nascimento-Castro, C | 1 |
| Wink, AC | 1 |
| da Fônseca, VS | 1 |
| Bianco, CD | 1 |
| Winkelmann-Duarte, EC | 1 |
| Farina, M | 3 |
| Rodrigues, ALS | 1 |
| Gil-Mohapel, J | 1 |
| de Bem, AF | 2 |
| Brocardo, PS | 1 |
| Mamo, JC | 1 |
| Lam, V | 1 |
| Al-Salami, H | 1 |
| Brook, E | 1 |
| Mooranian, A | 1 |
| Nesbit, M | 1 |
| Graneri, L | 1 |
| D'Alonzo, Z | 1 |
| Fimognari, N | 1 |
| Stephenson, A | 1 |
| Takechi, R | 1 |
| van der Sluis, RJ | 1 |
| Verwilligen, RAF | 1 |
| Lendvai, Z | 1 |
| Wever, R | 1 |
| Hoekstra, M | 1 |
| Van Eck, M | 1 |
| Erickson, RP | 2 |
| Borbon, IA | 1 |
| Zhou, G | 1 |
| Wang, Y | 5 |
| He, P | 2 |
| Li, D | 1 |
| Li, S | 2 |
| Liang, J | 1 |
| Niimi, M | 1 |
| Bilal Waqar, A | 1 |
| Kang, D | 1 |
| Koike, T | 1 |
| Shiomi, M | 1 |
| Fan, J | 1 |
| Guo, L | 1 |
| Zheng, Z | 1 |
| Ai, J | 1 |
| Howatt, DA | 1 |
| Mittelstadt, PR | 1 |
| Thacker, S | 1 |
| Daugherty, A | 2 |
| Ashwell, JD | 1 |
| Remaley, AT | 1 |
| Li, XA | 1 |
| Wu, R | 1 |
| Wu, X | 1 |
| Liu, B | 1 |
| Zhang, W | 1 |
| Gao, J | 1 |
| Zhang, X | 2 |
| Santos, DB | 1 |
| Colle, D | 2 |
| Moreira, ELG | 1 |
| Peres, KC | 1 |
| Ribeiro, RP | 1 |
| Dos Santos, AA | 1 |
| de Oliveira, J | 1 |
| Hort, MA | 1 |
| Peng, M | 1 |
| Ostrovsky, J | 1 |
| Kwon, YJ | 1 |
| Polyak, E | 1 |
| Licata, J | 1 |
| Tsukikawa, M | 1 |
| Marty, E | 1 |
| Thomas, J | 1 |
| Felix, CA | 1 |
| Xiao, R | 1 |
| Zhang, Z | 5 |
| Gasser, DL | 2 |
| Argon, Y | 1 |
| Falk, MJ | 2 |
| Wang, N | 1 |
| Wei, RB | 1 |
| Li, QP | 1 |
| Yang, X | 1 |
| Li, P | 1 |
| Huang, MJ | 1 |
| Wang, R | 1 |
| Cai, GY | 1 |
| Chen, XM | 1 |
| He, X | 2 |
| Yu, H | 2 |
| Bao, X | 1 |
| Cao, H | 2 |
| Yin, Q | 2 |
| Li, Y | 3 |
| Liu, G | 2 |
| Ji, W | 1 |
| Huang, J | 1 |
| Liu, L | 3 |
| Yakushiji, E | 1 |
| Ayaori, M | 1 |
| Nishida, T | 1 |
| Shiotani, K | 1 |
| Takiguchi, S | 1 |
| Nakaya, K | 1 |
| Uto-Kondo, H | 1 |
| Ogura, M | 1 |
| Sasaki, M | 1 |
| Yogo, M | 1 |
| Komatsu, T | 1 |
| Lu, R | 1 |
| Yokoyama, S | 1 |
| Ikewaki, K | 1 |
| Dan, Z | 1 |
| Zou, L | 1 |
| Zeng, L | 1 |
| Xu, Y | 1 |
| Xu, M | 1 |
| Zhong, D | 1 |
| Shen, Q | 1 |
| Zhang, P | 1 |
| Chen, Y | 1 |
| Pandiri, I | 1 |
| Joe, Y | 1 |
| Kim, HJ | 1 |
| Kim, SK | 1 |
| Park, J | 1 |
| Ryu, J | 1 |
| Cho, GJ | 1 |
| Park, JW | 1 |
| Ryter, SW | 1 |
| Chung, HT | 1 |
| Zhou, Z | 1 |
| Chen, S | 1 |
| Zhao, H | 1 |
| Wang, C | 1 |
| Gao, K | 1 |
| Guo, Y | 1 |
| Shen, Z | 1 |
| Wang, H | 1 |
| Mei, X | 1 |
| Kume, A | 1 |
| Anh, DT | 1 |
| Shichiri, M | 1 |
| Ishida, N | 1 |
| Suzuki, H | 1 |
| Kawamura, H | 1 |
| Takemoto, M | 1 |
| Maezawa, Y | 1 |
| Ishikawa, T | 1 |
| Ishibashi, R | 1 |
| Sakamoto, K | 1 |
| Shoji, M | 1 |
| Hattori, A | 1 |
| Yamaga, M | 1 |
| Ide, S | 1 |
| Ide, K | 1 |
| Hayashi, A | 1 |
| Tokuyama, H | 1 |
| Kobayashi, K | 1 |
| Yokote, K | 1 |
| Ishihara, M | 2 |
| Kojima, R | 1 |
| Ito, M | 2 |
| Motomura, G | 2 |
| Yamamoto, T | 2 |
| Miyanishi, K | 2 |
| Kondo, K | 1 |
| Hirota, Y | 1 |
| Iwamoto, Y | 2 |
| Gong, YT | 1 |
| Li, WM | 1 |
| Yang, SS | 1 |
| Sheng, L | 1 |
| Yang, N | 1 |
| Shan, HB | 1 |
| Xue, HJ | 1 |
| Liu, W | 1 |
| Yang, BF | 1 |
| Dong, DL | 1 |
| Li, BX | 1 |
| Zhou, SX | 1 |
| Zhou, Y | 1 |
| Zhang, YL | 1 |
| Lei, J | 1 |
| Wang, JF | 1 |
| Rappaport, EF | 1 |
| Yamamoto, S | 1 |
| Tanigawa, H | 1 |
| Li, X | 1 |
| Komaru, Y | 1 |
| Billheimer, JT | 1 |
| Rader, DJ | 1 |
| Fang, L | 1 |
| Green, SR | 1 |
| Baek, JS | 1 |
| Lee, SH | 1 |
| Ellett, F | 1 |
| Deer, E | 1 |
| Lieschke, GJ | 1 |
| Witztum, JL | 2 |
| Tsimikas, S | 1 |
| Miller, YI | 1 |
| Du, Y | 1 |
| Ji, H | 1 |
| Liu, H | 1 |
| Li, L | 1 |
| Hartwig, JM | 1 |
| Soares, FA | 1 |
| Hu, G | 1 |
| Zhao, Y | 1 |
| Tang, Y | 1 |
| Shen, J | 1 |
| Li, H | 1 |
| Liu, Y | 1 |
| Cui, X | 1 |
| Yu, Y | 1 |
| Guo, C | 1 |
| Wang, X | 1 |
| Horiuchi, K | 1 |
| Takatori, A | 1 |
| Inenaga, T | 1 |
| Ohta, E | 1 |
| Yamanouchi, J | 1 |
| Kawamura, S | 1 |
| Ishii, Y | 1 |
| Kyuwa, S | 1 |
| Yoshikawa, Y | 1 |
| Sundell, CL | 1 |
| Somers, PK | 1 |
| Meng, CQ | 1 |
| Hoong, LK | 1 |
| Suen, KL | 1 |
| Hill, RR | 1 |
| Landers, LK | 1 |
| Chapman, A | 1 |
| Butteiger, D | 1 |
| Jones, M | 1 |
| Edwards, D | 1 |
| Wasserman, MA | 1 |
| Alexander, RW | 1 |
| Medford, RM | 1 |
| Saxena, U | 1 |
| Braun, A | 1 |
| Zhang, S | 1 |
| Miettinen, HE | 1 |
| Ebrahim, S | 1 |
| Holm, TM | 1 |
| Vasile, E | 1 |
| Post, MJ | 1 |
| Yoerger, DM | 1 |
| Picard, MH | 1 |
| Krieger, JL | 1 |
| Andrews, NC | 1 |
| Simons, M | 1 |
| Krieger, M | 1 |
| Rabkin, DG | 2 |
| Weinberg, AD | 2 |
| Spotnitz, HM | 2 |
| Doggrell, SA | 1 |
| Yokoyama, T | 1 |
| Miyauchi, K | 2 |
| Kurata, T | 1 |
| Sato, H | 1 |
| Daida, H | 2 |
| Kim, W | 1 |
| Jeong, MH | 1 |
| Cha, KS | 1 |
| Hyun, DW | 1 |
| Hur, SH | 1 |
| Kim, KB | 1 |
| Hong, YJ | 1 |
| Park, HW | 1 |
| Kim, JH | 1 |
| Ahn, YK | 1 |
| Kim, MH | 1 |
| Cho, JG | 1 |
| Park, JT | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Curtis, LJ | 1 |
| Choy, K | 2 |
| Beck, K | 1 |
| Png, FY | 1 |
| Wu, BJ | 2 |
| Leichtweis, SB | 1 |
| Thomas, SR | 1 |
| Hou, JY | 1 |
| Croft, KD | 1 |
| Mori, TA | 1 |
| Stocker, R | 4 |
| Hirano, K | 1 |
| Ikegami, C | 1 |
| Tsujii, K | 1 |
| Matsuura, F | 1 |
| Nakagawa-Toyama, Y | 1 |
| Koseki, M | 1 |
| Masuda, D | 1 |
| Maruyama, T | 1 |
| Shimomura, I | 1 |
| Ueda, Y | 2 |
| Yamashita, S | 1 |
| Ved, R | 1 |
| Saha, S | 1 |
| Westlund, B | 1 |
| Perier, C | 1 |
| Burnam, L | 1 |
| Sluder, A | 1 |
| Hoener, M | 1 |
| Rodrigues, CM | 1 |
| Alfonso, A | 1 |
| Steer, C | 1 |
| Przedborski, S | 1 |
| Wolozin, B | 1 |
| Kondo, S | 1 |
| Shimizu, M | 1 |
| Urushihara, M | 1 |
| Tsuchiya, K | 1 |
| Yoshizumi, M | 1 |
| Tamaki, T | 1 |
| Nishiyama, A | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Quinn, MT | 1 |
| Lambeth, DJ | 1 |
| Kagami, S | 1 |
| Tanous, D | 1 |
| Bräsen, JH | 2 |
| Kathir, K | 1 |
| Lau, A | 1 |
| Celermajer, DS | 2 |
| Hong, SC | 1 |
| Zhao, SP | 1 |
| Wu, ZH | 1 |
| Okamoto, N | 1 |
| Murata, T | 1 |
| Tamai, H | 1 |
| Tanaka, H | 1 |
| Nagai, H | 1 |
| Ruixing, Y | 1 |
| Al-Ghazali, R | 1 |
| Wenwu, L | 1 |
| Jinzhen, W | 1 |
| Tanimoto, T | 1 |
| Nishida, K | 1 |
| Sueishi, K | 1 |
| Levander, OA | 1 |
| Fontela, R | 1 |
| Morris, VC | 1 |
| Ager, AL | 1 |
| Neale, TJ | 2 |
| Ojha, PP | 1 |
| Exner, M | 2 |
| Poczewski, H | 1 |
| Rüger, B | 1 |
| Davis, P | 1 |
| Kerjaschki, D | 3 |
| Ishida, K | 1 |
| Shi, K | 1 |
| Mizuno, A | 1 |
| Sano, T | 1 |
| Shima, K | 1 |
| Naito, H | 1 |
| Hirano, T | 1 |
| Yamaguchi, Y | 1 |
| Kitagawa, S | 1 |
| Imaizumi, N | 1 |
| Kunitomo, M | 1 |
| Fujiwara, M | 1 |
| O'Leary, VJ | 1 |
| Tilling, L | 1 |
| Fleetwood, G | 1 |
| Stone, D | 1 |
| Darley-Usmar, V | 1 |
| Magil, A | 1 |
| Sevanian, A | 2 |
| Hodis, H | 1 |
| Suzuki, Y | 2 |
| Binder, CJ | 1 |
| Weiher, H | 1 |
| Fruebis, J | 1 |
| Silvestre, M | 1 |
| Shelton, D | 1 |
| Napoli, C | 1 |
| Palinski, W | 1 |
| Nagao, S | 1 |
| Yamaguchi, T | 1 |
| Kasahara, M | 1 |
| Kusaka, M | 1 |
| Matsuda, J | 1 |
| Ogiso, N | 1 |
| Takahashi, H | 1 |
| Grantham, JJ | 1 |
| El-Swefy, S | 1 |
| Schaefer, EJ | 1 |
| Seman, LJ | 1 |
| van Dongen, D | 1 |
| Smith, DE | 1 |
| Ordovas, JM | 1 |
| El-Sweidy, M | 1 |
| Meydani, M | 1 |
| Lau, AK | 1 |
| Witting, PK | 2 |
| Chaufour, X | 1 |
| Pettersson, K | 1 |
| Nishimura, G | 1 |
| Yanoma, S | 1 |
| Satake, K | 1 |
| Ikeda, Y | 1 |
| Taguchi, T | 1 |
| Nakamura, Y | 1 |
| Hirose, F | 1 |
| Tsukuda, M | 1 |
| Pfuetze, KD | 1 |
| Dujovne, CA | 1 |
| Li, WG | 1 |
| Coppey, L | 1 |
| Weiss, RM | 1 |
| Oskarsson, HJ | 1 |
| Matsuno, H | 1 |
| Kozawa, O | 1 |
| Niwa, M | 1 |
| Abe, A | 1 |
| Takiguchi, Y | 1 |
| Uematsu, T | 1 |
| Yoshikawa, T | 2 |
| Shimano, H | 1 |
| Chen, Z | 1 |
| Ishibashi, S | 1 |
| Yamada, N | 1 |
| Camargo, F | 1 |
| Garver, WS | 1 |
| Hossain, GS | 1 |
| Carbone, PN | 1 |
| Heidenreich, RA | 1 |
| Blanchard, J | 1 |
| Inoue, K | 1 |
| Cynshi, O | 1 |
| Kawabe, Y | 1 |
| Nakamura, M | 1 |
| Kimura, T | 1 |
| Hamakubo, T | 1 |
| Yamaguchi, H | 1 |
| Kodama, T | 1 |
| Russell, JC | 1 |
| Yoshida, N | 1 |
| Murase, H | 1 |
| Kunieda, T | 1 |
| Toyokuni, S | 1 |
| Tanaka, T | 1 |
| Terao, J | 1 |
| Naito, Y | 1 |
| Tanigawa, T | 1 |
| Lin, SJ | 1 |
| Yang, TH | 1 |
| Chen, YH | 1 |
| Chen, JW | 1 |
| Kwok, CF | 1 |
| Shiao, MS | 1 |
| Chen, YL | 1 |
| Itoh, S | 1 |
| Umemoto, S | 1 |
| Hiromoto, M | 1 |
| Toma, Y | 1 |
| Tomochika, Y | 1 |
| Aoyagi, S | 1 |
| Tanaka, M | 1 |
| Fujii, T | 1 |
| Matsuzaki, M | 1 |
| Sia, YT | 1 |
| Lapointe, N | 1 |
| Parker, TG | 1 |
| Tsoporis, JN | 1 |
| Deschepper, CF | 1 |
| Calderone, A | 1 |
| Pourdjabbar, A | 1 |
| Jasmin, JF | 1 |
| Sarrazin, JF | 1 |
| Liu, P | 1 |
| Adam, A | 1 |
| Butany, J | 1 |
| Rouleau, JL | 1 |
| Koenig, K | 1 |
| Bach, H | 1 |
| Kontush, A | 1 |
| Heinle, H | 1 |
| Ylä-Herttuala, S | 1 |
| Beisiegel, U | 1 |
| Elharrar, V | 1 |
| Watanabe, AM | 1 |
| Molello, J | 1 |
| Besch, HR | 1 |
| Zipes, DP | 1 |
| Kisanuki, A | 1 |
| Asada, Y | 1 |
| Hatakeyama, K | 1 |
| Hayashi, T | 1 |
| Sumiyoshi, A | 1 |
| Rabinovitch, A | 1 |
| Suarez, WL | 1 |
| Power, RF | 1 |
| Kita, T | 3 |
| Ishii, K | 2 |
| Yokode, M | 2 |
| Kume, N | 2 |
| Nagano, Y | 3 |
| Otani, H | 1 |
| Arai, H | 1 |
| Kawai, C | 2 |
| Mori, Y | 1 |
| Wada, H | 1 |
| Deguchi, K | 1 |
| Shirakawa, S | 1 |
| Ooshima, A | 1 |
| Yoshida, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis[NCT00877604] | Phase 2 | 34 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy[NCT00050713] | Phase 2 | 12 participants (Actual) | Interventional | 2002-12-17 | Completed | ||
| Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy[NCT00977977] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-12-22 | Recruiting | ||
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period. (NCT00877604)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| TUDCA | 13 |
| Placebo | 6 |
7 reviews available for probucol and Disease Models, Animal
| Article | Year |
|---|---|
Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronar | 2003 |
[Research and developmental strategy of anti-dyslipidemic agents].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Apolipoprotein A-I; Carrier Proteins; Chole | 2007 |
[Animal models for steroid-induced osteonecrosis].
Topics: Animals; Anticholesteremic Agents; Anticoagulants; Disease Models, Animal; Dose-Response Relationshi | 2007 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Antioxidants and atherosclerosis: an overview.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Disease Models, Animal; Humans; P | 1997 |
Probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Arteriosclerosis; Cardiovascular | 2000 |
Type 2 diabetes: pharmacological intervention in an animal model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Calcium Channel Blockers; Diabe | 2001 |
79 other studies available for probucol and Disease Models, Animal
| Article | Year |
|---|---|
Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
Topics: Animals; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Diabetes Mellitus, Type 2; Disease Mod | 2017 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Effects and mechanisms of probucol on aging-related hippocampus-dependent cognitive impairment.
Topics: Age Factors; Animals; Behavior, Animal; Cellular Senescence; Cognition; Cognitive Dysfunction; Cycli | 2021 |
Probucol, a "non-statin" cholesterol-lowering drug, ameliorates D-galactose induced cognitive deficits by alleviating oxidative stress via Keap1/Nrf2 signaling pathway in mice.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cognition Disorders; Disease Models, Animal; Kelch- | 2019 |
Probucol Protects Rats from Cardiac Dysfunction Induced by Oxidative Stress following Cardiopulmonary Resuscitation.
Topics: Animals; Antioxidants; Cardiopulmonary Resuscitation; Disease Models, Animal; Glutathione Peroxidase | 2017 |
Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease.
Topics: Animals; Antidepressive Agents; Antioxidants; Cell Differentiation; Cell Proliferation; Cholesterol; | 2018 |
Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration.
Topics: Alginates; Animals; Biological Availability; Blood-Brain Barrier; Capsules; Diet, High-Fat; Disease | 2018 |
HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Bone Marrow; Bone Marrow Transplantation; Cholesterol, | 2018 |
Co-treatment with probucol does not improve lung pathology in hydroxypropyl-β-cyclodextrin-treated Npc1
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Cholesterol; Disease Models, Animal; Drug Combinations; | 2019 |
Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice.
Topics: Albuminuria; Animals; Antioxidants; Collagen Type IV; Diabetes Mellitus, Type 2; Disease Models, Ani | 2013 |
Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic | 2014 |
Scavenger receptor BI and high-density lipoprotein regulate thymocyte apoptosis in sepsis.
Topics: Animals; Apoptosis; Cecum; Cells, Cultured; Cholesterol, HDL; Corticosterone; Disease Models, Animal | 2014 |
[Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism].
Topics: Animals; Anticholesteremic Agents; Diet, High-Fat; Disease Models, Animal; Male; Non-alcoholic Fatty | 2014 |
Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Amyloid Precursor Protein Secretases; | 2015 |
Inhibiting cytosolic translation and autophagy improves health in mitochondrial disease.
Topics: Animals; Autophagy; Cell Survival; Cycloheximide; Cytosol; Disease Models, Animal; Electron Transpor | 2015 |
Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying Mechanism.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcysteine; Animals; Antioxidants; Contrast Media; Creatinine; Deox | 2015 |
pH-Responsive Wormlike Micelles with Sequential Metastasis Targeting Inhibit Lung Metastasis of Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, A | 2016 |
4-HNE expression in diabetic rat kidneys and the protective effects of probucol.
Topics: Aldehydes; Animals; Antioxidants; Biomarkers; Blotting, Western; Diabetes Mellitus, Experimental; Di | 2016 |
Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice.
Topics: Androstadienes; Animals; Anticholesteremic Agents; Aorta; Aortic Diseases; Apolipoprotein A-I; Apoli | 2016 |
A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer.
Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Breast Neoplasms; Cell Movement; Disease Models, | 2016 |
Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Cells, Cultured; Cilostazol; Disease Models | 2016 |
Probucol inhibits neural cell apoptosis via inhibition of mTOR signaling pathway after spinal cord injury.
Topics: Animals; Apoptosis; Autophagy; Caspase 3; Caspase 9; Cell Survival; Disease Models, Animal; Drug Eva | 2016 |
Probucol dramatically enhances dihydroartemisinin effect in murine malaria.
Topics: Animals; Antimalarials; Artemisinins; Chemoprevention; Disease Models, Animal; Malaria; Male; Mice, | 2016 |
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chemokine CCL2; Cilos | 2017 |
Influence of aging on gastric ulcer healing activities of the antioxidants alpha-tocopherol and probucol.
Topics: Acetic Acid; Administration, Oral; Aging; alpha-Tocopherol; Animals; Anti-Ulcer Agents; Antioxidants | 2008 |
Risk factors for developing osteonecrosis after prophylaxis in steroid-treated rabbits.
Topics: Adrenal Cortex Hormones; Animals; Anticholesteremic Agents; Anticoagulants; Biomarkers; Chemoprevent | 2008 |
Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing.
Topics: Animals; Antioxidants; Atrial Fibrillation; Blotting, Western; C-Reactive Protein; Cardiac Pacing, A | 2009 |
Antioxidant probucol attenuates myocardial oxidative stress and collagen expressions in post-myocardial infarction rats.
Topics: Animals; Antioxidants; Collagen; Collagen Type I; Collagen Type III; Diastole; Disease Models, Anima | 2009 |
Cross-platform expression microarray performance in a mouse model of mitochondrial disease therapy.
Topics: Animals; Antioxidants; Computational Biology; Disease Models, Animal; Gene Expression Profiling; Mic | 2010 |
Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding | 2011 |
In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish.
Topics: Animals; Animals, Genetically Modified; Antibodies, Monoclonal; Anticholesteremic Agents; Blood Vess | 2011 |
Probucol and atorvastatin in combination protect rat brains in MCAO model: upregulating Peroxiredoxin2, Foxo3a and Nrf2 expression.
Topics: Animals; Atorvastatin; Body Fluids; Brain; Disease Models, Animal; Drug Therapy, Combination; Forkhe | 2012 |
Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Topics: Animals; Antioxidants; Convulsants; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lip | 2012 |
Development of a novel model of hypertriglyceridemic acute pancreatitis in hamsters: protective effects of probucol.
Topics: Acute Disease; Amylases; Animals; Antioxidants; Biomarkers; Ceruletide; Cricetinae; Diet, High-Fat; | 2012 |
The effect of probucol on atherosclerosis in streptozotocin-induced diabetic-hyperlipidemic APA hamsters in different stages of atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Cricetinae; D | 2002 |
AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Disease | 2003 |
Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse.
Topics: Age Factors; Animals; Anticholesteremic Agents; Apolipoproteins E; CD36 Antigens; Cell Differentiati | 2003 |
Optimizing probucol administration to preserve left ventricular compliance after reperfusion injury in the heterotopic rat heart isograft.
Topics: Administration, Oral; Animals; Antioxidants; Disease Models, Animal; Heart Transplantation; Myocardi | 2003 |
Effect of probucol on neointimal thickening in a stent porcine restenosis model.
Topics: Animals; Antioxidants; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Probucol; Rand | 2004 |
Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model.
Topics: Animals; Antioxidants; Carbazoles; Carvedilol; Coronary Restenosis; Disease Models, Animal; Probucol | 2005 |
Na+/H+ exchange inhibition and antioxidants lack additive protective effects after reperfusion injury in the working heterotopic rat heart isograft.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Cardiac Volume; Compliance; Disease Models, Animal; D | 2005 |
Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis | 2005 |
Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.
Topics: Adult; Animals; Anticholesteremic Agents; Atherosclerosis; Carcinoma, Hepatocellular; Cell Line, Tum | 2005 |
Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans.
Topics: 3-Hydroxybutyric Acid; alpha-Synuclein; Amino Acid Sequence; Animals; Animals, Genetically Modified; | 2005 |
Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Biopsy, Needle; Blotting, Western; D | 2006 |
Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization.
Topics: Animals; Antioxidants; Cell Proliferation; Disease Models, Animal; Follow-Up Studies; Graft Occlusio | 2006 |
Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; CD36 Antigens; Cholesterol, HDL; Disease Models, Animal; Hepatocy | 2007 |
Effects of alpha tocopherol and probucol supplements on allergen-induced airway inflammation and hyperresponsiveness in a mouse model of allergic asthma.
Topics: Acrolein; Allergens; alpha-Tocopherol; Animals; Antioxidants; Asthma; Bronchial Hyperreactivity; Bro | 2006 |
Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion.
Topics: Animals; Apoptosis; Cardiotonic Agents; Disease Models, Animal; Male; Malondialdehyde; Myocardial Re | 2006 |
Protection against murine cerebral malaria by dietary-induced oxidative stress.
Topics: Animal Feed; Animals; Antioxidants; Disease Models, Animal; Fish Oils; Malaria, Cerebral; Male; Mice | 1995 |
Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.
Topics: Aldehydes; Animals; Anticholesteremic Agents; Antigen-Antibody Complex; Basement Membrane; Cholester | 1994 |
The effect of probucol on the development of non-insulin dependent diabetes mellitus in Otsuka Long Evans Tokushima Fatty (OLETF) rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Tolerance Test; L | 1994 |
Probucol suppresses the development of chronic renal failure in Dahl salt-sensitive rats: an animal model of spontaneous focal and segmental glomerulosclerosis.
Topics: Animals; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Kidney Failure, Chronic; Lipid | 1994 |
Enhancement of aortic cholesterol deposition by dietary linoleic acid in cholesterol-fed mice: an animal model for primary screening of antiatherosclerotic agents.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Desmo | 1993 |
The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy.
Topics: Administration, Oral; Animals; Antioxidants; Aortic Diseases; Arteriosclerosis; Blood; Copper; Disea | 1996 |
Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Chronic Disease; Disease Models, Animal; Disease | 1996 |
Anti-ulcer effects of antioxidants: effect of probucol.
Topics: Acetic Acid; Acute Disease; Animals; Anti-Ulcer Agents; Antioxidants; Chronic Disease; Cimetidine; D | 1998 |
Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy.
Topics: Aging; Albuminuria; Animals; Disease Models, Animal; Free Radical Scavengers; Glomerulosclerosis, Fo | 1999 |
Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits.
Topics: Animals; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Body Weight; Cholesterol, Dietary; Copper; | 1999 |
Effect of probucol in a murine model of slowly progressive polycystic kidney disease.
Topics: Animals; Anticholesteremic Agents; Disease Models, Animal; Disease Progression; Male; Mice; Mice, In | 2000 |
The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Cells, Cultured | 2000 |
Protective effects of probucol in two animal models of atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Apolipoproteins E; Arterioscle | 2000 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
Antioxidant therapy attenuates JNK activation and apoptosis in the remote noninfarcted myocardium after large myocardial infarction.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apoptosis; Disease Models, Animal; Enzyme Activatio | 2001 |
Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters.
Topics: Animals; Becaplermin; Blood Flow Velocity; Carotid Arteries; Carotid Artery Thrombosis; Cells, Cultu | 2001 |
Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Arteriosclerosis; Cholesterol; Cholesterol, HD | 2001 |
Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Anticholesteremic Agents; Ataxia; beta-Cyclodextrins; Bl | 2001 |
Effect of BO-653 and probucol on c-MYC and PDGF-A messenger RNA of the iliac artery after balloon denudation in cholesterol-fed rabbits.
Topics: Analysis of Variance; Animals; Antioxidants; Arteriosclerosis; Base Sequence; Benzofurans; Catheteri | 2002 |
Inhibitory effect of a novel water-soluble vitamin E derivative on atherosclerosis in rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta; Arteriosclerosis; Aspartate Aminotransferases; B | 2002 |
Effects of Ginkgo biloba extract on the proliferation of vascular smooth muscle cells in vitro and on intimal thickening and interleukin-1beta expression after balloon injury in cholesterol-fed rabbits in vivo.
Topics: Angioplasty, Balloon; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Arterios | 2002 |
Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis.
Topics: Actins; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Choleste | 2002 |
Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat.
Topics: Animals; Antioxidants; Apoptosis; Atrial Natriuretic Factor; Chronic Disease; Disease Models, Animal | 2002 |
Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits.
Topics: alpha-Tocopherol; Animals; Antioxidants; Aorta; Arteriosclerosis; Coenzymes; Disease Models, Animal; | 2002 |
Adrenergaically mediated ventricular fibrillation in probucol-treated dogs: roles of alpha and beta adrenergic receptors.
Topics: Angiotensin II; Animals; Death, Sudden; Disease Models, Animal; Dogs; Dose-Response Relationship, Dr | 1979 |
Contribution of the endothelium to intimal thickening in normocholesterolemic and hypercholesterolemic rabbits.
Topics: Animals; Arteriosclerosis; Cell Division; Disease Models, Animal; Hypercholesterolemia; Immunohistoc | 1992 |
Combination therapy with an antioxidant and a corticosteroid prevents autoimmune diabetes in NOD mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 1; Disease M | 1992 |
Lipoproteins and atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol Esters; Cholestyramine | 1990 |
Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation.
Topics: Aging; Animals; Arteriosclerosis; Blood Coagulation Factors; Disease Models, Animal; Hyperlipidemias | 1989 |
Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Disease Models, Animal; Female; Hyperlipopr | 1987 |